Phase 3 Alzheimer's Disease Trial, Recruiting NCT07571161 Sponsor: Eli Lilly and Company Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07571161
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You scored 35 or higher on a phone-based memory and thinking test, suggesting your cognitive function is intact
  • A doctor's assessment of your memory and thinking (called a CDR-GS) showed a score of 0, meaning no signs of cognitive decline were detected
  • A blood test result suggests the presence of a certain protein pattern in your body linked to Alzheimer's-related brain changes
  • You have a trusted person in your life (such as a family member or close friend) who is willing to formally take part in the study, is 18 or older, knows you well and sees you regularly, and can complete some questionnaires about your daily functioning
  • You are able to read, see, and hear well enough to complete memory and thinking tests

Who may not be able to join:

  • You have been diagnosed with mild cognitive impairment (MCI), dementia, or another condition that affects brain function
  • You have a serious or unstable health condition affecting your heart, liver, kidneys, lungs, gut, hormones, nerves, mental health, immune system, or blood — or any condition that, in the doctor's view, could interfere with the study or means you may have 5 years or fewer to live
  • You have previously received any vaccine or treatment targeting a brain protein called amyloid beta, in any other study
  • You currently take or have previously taken prescription medication to treat MCI or Alzheimer's disease
  • You are unable to have an MRI scan — for example, due to claustrophobia, or because you have certain metal implants or devices in your body such as a pacemaker, stent, or cochlear implant
  • A review of your brain MRI scan showed certain abnormalities, such as specific types of bleeding, fluid changes, or significant changes to the brain's white matter (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
30 April 2026
Est. completion
1 April 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov